graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process of homology directed repair (hdr) and targeted dna integration to precisely repair genetic defects at their source. graphite bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients’ lives
Company profile
Ticker
LENZ
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Integral Medicines, Inc.
SEC CIK
Corporate docs
IRS number
844867570
LENZ stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
11 Apr 24
424B3
Prospectus supplement
10 Apr 24
S-1/A
IPO registration (amended)
8 Apr 24
8-K
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
3 Apr 24
S-1
IPO registration
29 Mar 24
8-K
Report of Independent Registered Public Accounting Firm
21 Mar 24
8-K
Regulation FD Disclosure
19 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
14 Mar 24
425
Business combination disclosure
8 Mar 24
8-K
Graphite Bio Declares Special Dividend
8 Mar 24
Latest ownership filings
SC 13G/A
EcoR1 Capital, LLC
8 Apr 24
3
Initial statement of insider ownership
28 Mar 24
SC 13G
Alpha Wave Ventures GP, Ltd
28 Mar 24
SC 13D
RA CAPITAL MANAGEMENT, L.P.
28 Mar 24
4
Rajeev M. Shah
25 Mar 24
3
Rajeev M. Shah
25 Mar 24
4
Shelley B Thunen
25 Mar 24
SC 13G/A
Samsara BioCapital, L.P.
25 Mar 24
4
JAMES W MCCOLLUM
25 Mar 24
4
Frederic Guerard
25 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 186.42 mm | 186.42 mm | 186.42 mm | 186.42 mm | 186.42 mm | 186.42 mm |
Cash burn (monthly) | (no burn) | (no burn) | 8.34 mm | 11.37 mm | 3.13 mm | 5.55 mm |
Cash used (since last report) | n/a | n/a | 57.03 mm | 77.70 mm | 21.42 mm | 37.92 mm |
Cash remaining | n/a | n/a | 129.39 mm | 108.72 mm | 165.00 mm | 148.50 mm |
Runway (months of cash) | n/a | n/a | 15.5 | 9.6 | 52.7 | 26.8 |
Institutional ownership, Q3 2023
91.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 67 |
Opened positions | 11 |
Closed positions | 13 |
Increased positions | 22 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 75.50 bn |
Total shares | 53.55 mm |
Total puts | 500.00 |
Total calls | 700.00 |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Versant Venture Capital VI | 14.71 mm | $405.95 mm |
EcoR1 Capital | 8.54 mm | $21.18 bn |
Samsara BioCapital | 8.46 mm | $0.00 |
Samsara BioCapital | 8.46 mm | $20.98 bn |
Tang Capital Management | 2.02 mm | $5.00 bn |
BLK Blackrock | 1.80 mm | $4.48 bn |
Vanguard | 1.38 mm | $3.43 bn |
Prosight Management | 1.34 mm | $3.32 bn |
Citadel Advisors | 1.24 mm | $3.08 bn |
Board of Trustees of The Leland Stanford Junior University | 703.07 k | $1.74 bn |
News
Leerink Partners Initiates Coverage On LENZ Therapeutics with Outperform Rating, Announces Price Target of $32
15 Apr 24
William Blair Initiates Coverage On LENZ Therapeutics with Outperform Rating
15 Apr 24
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
10 Apr 24
Citigroup Initiates Coverage On LENZ Therapeutics with Buy Rating, Announces Price Target of $34
10 Apr 24
Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study
3 Apr 24
Press releases
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
3 Apr 24
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
2 Apr 24
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
8 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EVRI, SCTL, FIXX, GRPH
1 Mar 24
Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm
1 Mar 24